Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, D-66421 Homburg, Germany.
Int J Mol Sci. 2023 May 31;24(11):9576. doi: 10.3390/ijms24119576.
In the absence of targeted treatment options, neoadjuvant chemotherapy (NACT) is applied widely for triple-negative breast cancer (TNBC). Response to NACT is an important parameter predictive of oncological outcomes (progression-free and overall survival). An approach to the evaluation of predictive markers enabling therapy individualization is the identification of tumor driver genetic mutations. This study was conducted to investigate the role of , harbored at 3q26 and identified as a driver of breast cancer pathogenesis, in TNBC. We analyzed expression in The Cancer Genome Atlas database, and immunohistologically investigated expression in pre- and post-NACT tissue samples from 64 patients with TNBC treated at the Department of Gynecology and Obstetrics/Saarland University Hospital/Homburg between January 2010 and December 2018 and compared the effect of on tumor cell migration and proliferation in functional assays. expression dynamics correlated positively with the response to NACT ( ≤ 0.01) and oncological outcomes ( ≤ 0.01). expression stimulated tumor cell migration ( ≤ 0.01). The study findings indicate that is overexpressed in TNBC and serves as a predictive marker for the response to NACT, a prognostic marker for oncological outcomes, and a migration-stimulating oncogene in TNBC.
在缺乏靶向治疗选择的情况下，新辅助化疗（NACT）广泛应用于三阴性乳腺癌（TNBC）。对 NACT 的反应是预测肿瘤学结果（无进展生存期和总生存期）的一个重要参数。一种能够实现个体化治疗的预测标志物评估方法是鉴定肿瘤驱动基因的突变。本研究旨在探讨 3q26 上的 基因，其被鉴定为乳腺癌发病机制的驱动基因，在 TNBC 中的作用。我们分析了癌症基因组图谱数据库中的 表达，并对 2010 年 1 月至 2018 年 12 月在妇产科/萨尔兰大学医院/洪堡就诊的 64 例接受 NACT 治疗的 TNBC 患者的术前和术后组织样本进行了 免疫组织化学分析，并比较了 在功能测定中对肿瘤细胞迁移和增殖的影响。 表达动力学与 NACT 反应呈正相关（ ≤ 0.01）和肿瘤学结果（ ≤ 0.01）。 表达刺激肿瘤细胞迁移（ ≤ 0.01）。研究结果表明，在 TNBC 中过度表达，是 NACT 反应的预测标志物、肿瘤学结果的预后标志物和 TNBC 中促进迁移的致癌基因。
